Posted on by Cynthia Johnson

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

NCT#: & LinkNCT04613596
NCT QR Code
Available as of:July 15 2024
Contract:Caris
Indication Category:Lung
Study Sponsor:Mirati Therapeutics
Protocol #:849-007
Title:Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
Highlight Details:A Phase 2 Trial of Adagrasib Monotherapy and  in Combination with Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination with Pembrolizumab versus Pembrolizumab in Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
Biomarkers:KRAS G12C
Indication:NSCLC
Phase:3
Treatment Line:
Study Drug/Test Compound:Adagrasib
Notes
Recruitment Status:Just In Time
Participating Institution:Salinas Valley Health
Salinas Valley Health Clinical Research Program:Terri Nielsen, MSJ, RN, CCRP, Clinical Research Program Manager, [email protected]